What's Happening?
Serif Biomedicines, a company under Flagship Pioneering, has announced promising preclinical data on its Modified DNA platform at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2026. The data highlights the potential of Modified DNA to
overcome significant barriers that have historically limited DNA's use as a therapeutic modality, such as innate immune activation and inefficient nuclear access. The platform demonstrated systemic tolerability in non-human primates and enhanced gene expression with proprietary mRNA co-factors. Additionally, the Modified DNA showed sustained and durable liver expression and in vivo CAR expression with complete B-cell depletion in a humanized mouse model. These findings suggest that Modified DNA could serve as a new class of genetic medicines, offering longer gene expression without permanent genome integration.
Why It's Important?
The development of Modified DNA as a therapeutic modality could significantly impact the field of genetic medicine. By addressing the challenges of innate immune activation and nuclear access, Serif Biomedicines' platform may enable more effective treatments for genetically defined diseases and immune cell programming. This advancement could lead to new therapies for rare diseases and conditions requiring precise genetic interventions. The ability to achieve sustained gene expression and functional activity in vivo suggests that Modified DNA could offer advantages over existing genetic medicine approaches, potentially leading to more durable and redosable treatments. This innovation could benefit patients with conditions that currently have limited treatment options, enhancing the overall landscape of genetic therapies.
What's Next?
Serif Biomedicines plans to continue developing its Modified DNA platform, focusing on genetically defined diseases and immune system reprogramming. The company aims to further validate its preclinical findings and explore potential clinical applications. As the platform progresses, it may attract interest from pharmaceutical companies and researchers seeking to develop new genetic therapies. Regulatory pathways will need to be navigated to bring these therapies to market, and ongoing research will be crucial to demonstrate safety and efficacy in human trials. The success of this platform could pave the way for broader adoption of Modified DNA in various therapeutic areas.
